KCNQ2 encodes Kv7.2, a voltage-gated potassium channel subunit that forms the M-current, a critical regulator of neuronal excitability. Pathogenic variants in KCNQ2 cause two distinct disorders depending on the functional consequence: gain-of-function variants produce benign familial neonatal seizures (BFNS), while loss-of-function variants cause KCNQ2 encephalopathy, a severe developmental and epileptic encephalopathy.
KCNQ2 is one of the most commonly identified genes in early-onset neonatal epilepsies, accounting for approximately 5-10% of cases. The gene is also notable because many patients with KCNQ2 encephalopathy experience significant seizure improvement in the first 1-3 years of life, distinguishing it from other DEEs[@kcnq2gene2022].
| Property | Value |
|---|---|
| Gene Symbol | KCNQ2 |
| Chromosomal Location | 20q13.33 |
| Genomic Coordinates | chr20:62,030,000-62,100,000 (GRCh38) |
| Gene Length | ~50 kb |
| Number of Exons | 19 coding exons |
| Transcript Length | ~2.4 kb coding sequence |
| Protein Length | 844 amino acids |
| Protein Class | Voltage-gated potassium channel (Kv7 family) |
| Expression | Brain (neurons throughout forebrain, highest in cortex, hippocampus, brainstem) |
| OMIM | 602235 |
| UniProt | O43726 |
Kv7.2 contains six transmembrane segments (S1-S6):
Kv7.2 functions as a tetramer, either as a homomeric channel (four Kv7.2 subunits) or as a heteromeric channel with Kv7.3 (KCNQ3). The predominant neuronal composition is Kv7.2:Kv7.3 heterotetramers in a 2:2 or 3:1 ratio.
The M-current (named for its inhibition by muscarinic acetylcholine receptor activation) is a non-inactivating K+ current that activates at voltages near the threshold for action potential firing. It serves as a "brake" on neuronal excitability:
Gain-of-function variants increase M-current amplitude or shift activation to more negative voltages. This hyperpolarizes neurons, making them harder to fire. The result is benign familial neonatal seizures (BFNS) — self-limited seizures that typically resolve within the first year of life with normal neurodevelopment.
Loss-of-function variants reduce M-current, leading to:
The paradox of severe early seizures followed by improvement may reflect:
| Disorder | Variant Type | Inheritance | Key Features |
|---|---|---|---|
| KCNQ2 encephalopathy | Loss-of-function (missense, nonsense, truncating) | De novo (majority) | Neonatal seizures, burst suppression EEG, developmental impairment |
| Benign familial neonatal seizures (BFNS) | Gain-of-function (missense) | Autosomal dominant | Self-limited neonatal seizures, normal development |
| Early-onset epileptic encephalopathy | Severe loss-of-function | De novo | Very early onset, more severe phenotype |
Ezogabine (potassium channel opener, FDA-approved for focal seizures) increases M-current by enhancing Kv7 channel opening. Case reports suggest benefit in KCNQ2 encephalopathy, though evidence is limited. Cardiac monitoring required (QT prolongation risk).
KCNQ2 is an excellent gene therapy target:
See clinical trial page for KCNQ2 encephalopathy and therapeutics hub page.